Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...
Eczema affects an estimated 20 per cent of children and 11 per cent of adults in Singapore. In its moderate to severe form, ...
Get detailed information on Dupilumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...
Wells Fargo analyst Derek Archila maintained a Buy rating on AnaptysBio (ANAB – Research Report) yesterday and set a price target of ...
GlobalData on MSN6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialA Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the publication of a case study highlighting the use of ...
The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...
Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback